Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Imugene Limited ( (AU:IMU) ) has provided an update.
Imugene Limited announced that all resolutions were passed at their Extraordinary General Meeting, marking a positive step for the company. This successful outcome may enhance Imugene’s operational capabilities and strengthen its positioning within the immuno-oncology sector, with potential implications for stakeholders and the company’s future growth.
More about Imugene Limited
Imugene Limited is a clinical stage immuno-oncology company focused on developing innovative immunotherapies to activate the immune system of cancer patients for tumor treatment and eradication. Their platform technologies aim to harness the body’s immune system against tumors, potentially achieving effects similar to or greater than conventional monoclonal antibodies and other immunotherapies. The company’s pipeline includes an allogeneic cell therapy CAR T drug, azer-cel, targeting CD19 for blood cancers, multiple immunotherapy B-cell vaccine candidates, and an oncolytic virotherapy, CF33, for various cancers. Imugene is supported by international cancer experts, is well-funded, and aims to become a foundation treatment provider in the rapidly growing global cancer treatment market.
YTD Price Performance: 25.00%
Average Trading Volume: 164,421
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $190.5M
For detailed information about IMU stock, go to TipRanks’ Stock Analysis page.
